Surveillance of BRCA1 and BRCA2 Mutation Carriers With Magnetic Resonance Imaging, Ultrasound, Mammography, and Clinical Breast Examination

Ellen Warner, MD
Donald B. Plewes, PhD
Kimberley A. Hill, BA
Petrina A. Causer, MD
Judit T. Zubovits, MD
Roberta A. Jong, MD
Margaret R. Cutrara, RN
Gerrit DeBoer, PhD
Martin J. Yaffe, PhD
Sandra J. Messner, MD
Cameron A. Piron, MSc
Steven A. Narod, MD

Context  Current recommendations for women who have a BRCA1 or BRCA2 mutation are to undergo breast surveillance from age 25 years onward with mammography annually and clinical breast examination (CBE) every 6 months; however, many tumors are detected at a relatively advanced stage. Magnetic resonance imaging (MRI) and ultrasound may improve the ability to detect breast cancer at an early stage.

Objective  To compare the sensitivity and specificity of 4 methods of breast cancer surveillance (mammography, ultrasound, MRI, and CBE) in women with hereditary susceptibility to breast cancer due to a BRCA1 or BRCA2 mutation.

Design, Setting, and Participants  A surveillance study of 236 Canadian women aged 25 to 65 years with BRCA1 or BRCA2 mutations who underwent 1 to 3 annual screening examinations, consisting of MRI, mammography, and ultrasound at a single tertiary care teaching hospital between November 3, 1997, and March 31, 2003. On the day of imaging and at 6-month intervals, CBE was performed.

Main Outcome Measures  Sensitivity and specificity of each of the 4 surveillance modalities, and sensitivity of all 4 screening modalities vs mammography and CBE.

Results  Each imaging modality was read independently by a radiologist and scored on a 5-point Breast Imaging Reporting and Data System scale. All lesions with a score of 4 or 5 (suspicious or highly suspicious for malignancy) were biopsied. There were 22 cancers detected (16 invasive and 6 ductal carcinoma in situ). Of these, 17 (77%) were detected by MRI vs 8 (36%) by mammography, 7 (33%) by ultrasound, and 2 (9.1%) by CBE. The sensitivity and specificity (based on biopsy rates) were 77% and 99.8% for MRI, 36% and 96% for mammography, 33% and 96% for ultrasound, and 9.1% and 99.3% for CBE, respectively. There was 1 interval cancer. All 4 screening modalities combined had a sensitivity of 95% vs 45% for mammography and CBE combined.

Conclusions  In BRCA1 and BRCA2 mutation carriers, MRI is more sensitive for detecting breast cancers than mammography, ultrasound, or CBE alone. Whether surveillance regimens that include MRI will reduce mortality from breast cancer in high-risk women requires further investigation.

JAMA. 2004;292:1317-1325
www.jama.com

For editorial comment see p 1368.

©2004 American Medical Association. All rights reserved.
these trials would have a BRCA mutation. Nonrandomized observational studies of cohorts of BRCA mutation carriers undergoing routine mammographic screening have demonstrated that approximately 50% of the breast tumors are detected at screening and 50% present as interval cancers between screening mammograms.5,6

Contrast-enhanced magnetic resonance imaging (MRI) of the breast has been shown to have high sensitivity for detecting early breast cancer, albeit with lower specificity than mammography, and is not affected by breast density.7 A number of studies have suggested that MRI surveillance may benefit women at high risk8-15 but the sensitivity and specificity of MRI for BRCA mutation carriers have not been fully evaluated in the screening setting. Ultrasound of the breast is less practical than mammography for screening the general population because of its lower specificity and its dependency on operator experience.16 However, it has been found in several studies17 that ultrasound is more sensitive than mammography for screening women with dense breasts, and ultrasound may be particularly useful for the surveillance of young women at high risk.

To determine the extent to which MRI and ultrasound increase the ability to detect small breast cancers in BRCA1 and BRCA2 mutation carriers beyond that of mammography and CBE, and to estimate the sensitivity of this combined screening regimen, we screened 236 mutation carriers with all 4 modalities on an annual basis for up to 3 years.

METHODS

Study Population

Between November 3, 1997, and March 31, 2003, 236 female BRCA1 and BRCA2 mutation carriers between 25 and 65 years were recruited from familial cancer clinics in southern Ontario and Montreal, Canada. Women with a past history of unilateral breast cancer were eligible if the contralateral breast was intact. Pregnant or lactating women were asked to defer their participation. Women with a history of bilateral breast cancer, who were currently undergoing chemotherapy, or who were known to have metastatic disease were excluded. Women who weighed more than 91 kg were excluded for technical reasons. Participation in the study was offered to all eligible women in the context of genetic counseling. Women were invited to contact the study coordinator (K.A.H.) directly if they wished to participate. Informed consent was obtained from all participants. Preliminary results for the first round of screening of the first 96 patients were reported in a previous publication.18

Study Protocol

The study was approved by the institutional review boards of the participating institutions. Eligible women were invited to begin the screening protocol after at least 1 year had passed since their last mammogram. The protocol consisted of an intake questionnaire that included, among other demographic factors, an open-ended question on maternal and paternal ethnicity (included because we thought the information might be meaningful), and evaluation by 4 screening modalities: CBE, mammography, screening ultrasound, and MRI. All 4 were performed on the same day at the Sunnybrook campus of the Sunnybrook and Women’s College Health Sciences Centre, Toronto, Ontario. For premenopausal women, screening was performed during the second week of the menstrual cycle to minimize the occurrence of breast densities or of enhancing masses related to cyclical hormonal variation. For women with a past history of breast cancer who had undergone breast-conserving surgery, bilateral breast screening was performed. For those women who had undergone unilateral mastectomy, screening of the contralateral breast was performed. Each imaging study was read and scored independently by a different radiologist (P.A.C. and R.A.J.) who specialized in breast imaging. Radiologists were blinded to the results of the CBE. Imaging was repeated annually and CBE was performed every 6 months.

Clinical Breast Examination

Physical examination of the breasts and regional lymphatic areas was performed at 6-month intervals by either a physician or a registered nurse (E.W., M.R.C., and S.J.M.) experienced in breast examination. Each examination was coded as normal, suggestive of benign disease, indeterminate, or suspicious for malignancy. Indeterminate examinations were repeated 3 months later.

Mammography

Conventional 4-view film/screen mammograms were reviewed by a single radiologist (P.A.C. or R.A.J.). Further views were performed when judged to be necessary. Mammograms were scored on a 5-point scale, using the American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) categories (0 = needs further work-up; 1 = negative; 2 = benign finding; 3 = probably benign finding, short follow-up interval suggested; 4 = suspicious abnormality, biopsy should be considered; 5 = highly suggestive of malignancy).19

Magnetic Resonance Imaging

Simultaneous bilateral MRI was performed by using a 1.5-T magnet (Signa, General Electric Medical Systems, Milwaukie, Wis). The first 38 patients were imaged in the first year of the study with a single turn elliptical coil after a bolus injection of 0.1 mmol/kg of gadolinium-diethylenetriamine penta-acetic acid (Omniscan, GE Healthcare, Oakville, Ontario). After appropriate imaging to localize the breast, bilateral 3-dimensional spoiled gradient recalled images (SPGR) were collected in the coronal plane (repetition time [TR]/echo time [TE]/flip angle, 12.9 ms/43 ms/20° with 28 slices of 4-6 mm thickness), preinjection, and for a period of 10 minutes postinjection. The scan time for each 3-dimensional data set was 90 seconds. For all subsequent scans, a phased-array coil arrangement was used,20 which
provided sagittal images with a 2.5-fold greater signal-to-noise ratio. The protocol includes a localizing sequence, sagittal, fat-suppressed T2-weighted Fast Spin Echo (TR/TE, 4000 ms/102 ms), followed by simultaneous sagittal imaging of both breasts using dual 3-dimensional sagittal TR-interleaved SPGR sequences (TR/TE/flip angle, 18.4 ms/4.3 ms/40° from 28 partitions per breast) as proposed by Greenman et al. Imaging was performed both before and after a rapid intravenous injection of 0.1 mmol/kg of gadolinium-diethylene triamine penta-acetic acid. Each volumetric bilateral acquisition was obtained in 2 minutes 49 seconds. Slice thickness was 2 to 3 mm, without a gap, using a matrix of 256 × 256 and a field of view of 18 to 20 cm. Frequency was in the anteroposterior direction. Precontrast images were subtracted from postcontrast images to suppress the fat signal.

In cases in which a potentially suspicious area of enhancement was detected, a diagnostic MRI scan was performed, which comprised a set of high temporal and spatial resolution unilateral MRI scans of the suspicious breast. During the first 2 minutes postinjection, dynamic images were acquired in the form of 9 adjacent, 2-dimensional SPGR with fat saturation (TR/TE/flip angle, 150 ms/4.2 ms/50°) that allowed dynamic monitoring of tissue enhancement with a temporal resolution of 20 seconds. This was followed by a single high spatial resolution 3-dimensional SPGR scan with fat saturation (TR/TE/flip angle/matrix/slice thickness, 50 ms/4.2 ms/50°/256 × 512/1 mm) that took 7 minutes. This was then followed up by an additional series of dynamic images to monitor contrast media washout. The scanning time for the entire set of images was 10 minutes. These images were used to help further characterize the lesion morphology and to provide kinetic enhancement characteristics for clinical management.

The MRI results were initially scored according to the preliminary BI-RADS classification. Assessment was based primarily on morphology, using enhancement kinetics for indeterminate and presumed benign lesions. The criteria included mass vs nonmass enhancement and symmetry of enhancement. Enhancement patterns were assessed both qualitatively and quantitatively, using time-signal intensity curves (including the degree of enhancement and the delayed enhancement pattern). Cases with a detected abnormality were classified as follows. Cases for which the diagnosis of a specific benign condition was presumed (the presence of nonenhancing internal septations in a circumscribed or lobulated mass with no washout on delayed imaging for fibroadenoma, rim enhancement associated with an inflamed cyst, or a reniform shaped intramammary lymph node with a feeding vessel to the hilum) were classified as BI-RADS 2. Cases with a focus or a symmetric diffuse enhancement pattern were also classified as BI-RADS 2. Nonmass lesions with features that were predictive of malignancy (asymmetric clumped enhancement in a ductal, linear, or segmental distribution) were classified as BI-RADS 4. Masses that possessed features that were predictive of malignancy (spiculated or irregular margins, rim enhancement, irregular shape associated with early enhancement with washout during delayed phase) were classified as BI-RADS 5. If a mass did not possess features whereby a specific benign condition could be diagnosed, it was considered to be BI-RADS 4 or 5. Masses that were believed to be due to fibroadenomas or to intramammary lymph nodes but could not be confidently classified as such, or asymmetric nonmass enhancements that did not fall into the previously mentioned categories, were classified as BI-RADS 3. Women with BI-RADS 3 lesions did not routinely undergo biopsy but were followed up at 6 months, 1 year, and 2 years after the initial imaging study. If a lesion resolved, decreased, or remained stable during 2 years, it was reclassified as BI-RADS 2.

Ultrasound
High-resolution ultrasound was performed using a 7.5-MHz transducer by a technologist supervised by an experienced physician (P.A.C. or R.A.J.) and blinded to the other imaging studies. The reports were coded using a preliminary BI-RADS ultrasound lexicon. Any solid lesion, unless benign by criteria established by Stavros et al, was considered to be suspicious enough for cancer to warrant a biopsy. The first 7 patients did not receive ultrasound.

Biopsies
A biopsy was recommended if 1 of CBE, mammogram, MRI examination, or ultrasonography was judged to be suspicious for cancer (BI-RADS categories: 4 or 5 or equivalent). If the MRI screening test was abnormal (BI-RADS: 3, 4, or 5) but no other modality was abnormal, a diagnostic MRI procedure was performed approximately 4 weeks later. Cases that were suspicious for malignancy on diagnostic MRI examination (BI-RADS: 4 or 5) proceeded to biopsy. If a lesion was detected only by MRI, the mammograms were reviewed and a targeted second-look ultrasound was performed to help guide the biopsy. Any lesion detected by the targeted ultrasound was correlated with the MRI by lesion morphology, size, and location to ensure that the ultrasound visible lesion corresponded with the MRI lesion prior to biopsy.

Core and excisional biopsies were performed under ultrasound or stereotactic guidance, with the exception of 10 women for whom the abnormality was visualized by MRI but was not observed with directed ultrasound or mammography. In these cases an excisional biopsy was performed using an MRI-guided wire localization technique similar to that proposed by Orel et al. This device consisted of 2 fenestrated plates that provide medial-lateral compression of the breast. Fine needle positioning within these fenestrations (a set of 6 × 8 square, 5/8” apertures) was performed using guide plugs accommodating needles of various gauge sizes (20, 14, and 9 gauges). These drilled guide holes provided a means of delivering the needle into the breast through a finite number of positions. Attached to these
BRCA1 AND BRCA2 MUTATION CARRIERS

Table 1. Characteristics of Study Participants (N = 236)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>No. of Participants (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at first screening, mean (range), y</td>
<td>46.6 (26.4-64.8)</td>
</tr>
<tr>
<td>Mutation status</td>
<td></td>
</tr>
<tr>
<td>BRCA1</td>
<td>137 (58)</td>
</tr>
<tr>
<td>BRCA2</td>
<td>99 (42)</td>
</tr>
<tr>
<td>Ethnicity*</td>
<td></td>
</tr>
<tr>
<td>Ashkenazi Jewish</td>
<td>73 (31)</td>
</tr>
<tr>
<td>Other</td>
<td>163 (69)</td>
</tr>
<tr>
<td>Cancer history</td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>70 (30)</td>
</tr>
<tr>
<td>Ovary</td>
<td>22 (9)</td>
</tr>
<tr>
<td>None or other</td>
<td>144 (60)</td>
</tr>
<tr>
<td>Menopausal status</td>
<td></td>
</tr>
<tr>
<td>Premenopausal</td>
<td>106 (45)</td>
</tr>
<tr>
<td>Postmenopausal</td>
<td>130 (55)</td>
</tr>
<tr>
<td>Rounds of screening completed</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>236 (100)</td>
</tr>
<tr>
<td>2</td>
<td>136 (58)</td>
</tr>
<tr>
<td>3</td>
<td>85 (36)</td>
</tr>
</tbody>
</table>

*Ethnicity was indicated by study participant via a questionnaire.

Table 2

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity</td>
<td>0.86</td>
</tr>
<tr>
<td>Specificity</td>
<td>0.87</td>
</tr>
<tr>
<td>Positive predicative value (PPV)</td>
<td>0.87</td>
</tr>
</tbody>
</table>

Sensitivity was defined as the number of cancers detected by a given modality (or combination of modalities) divided by the total number of cancers detected by all 4 modalities plus interval cancers during the entire 3-year study period (from the date of first screen to 1 year following the last screen). Differences in the relative sensitivity of each modality were compared with Fisher exact test. As sensitivities of overlapping combinations of screening modalities are not independent when applied to the same patients without blinded repetition, statistical testing of comparisons between them was not performed. The positive predictive value (PPV) for each modality was defined as the number of biopsy-proven cancers as a proportion of the number of suspicious studies (BI-RADS: 4 or 5 equivalent) that resulted in a biopsy. Specificity was defined as the number of true-negative results divided by the sum of true-negative results and false-positive results (ie, examinations leading to a negative biopsy). These definitions of PPV and specificity did not include in the denominators women who had additional diagnostic studies that did not result in a biopsy. The negative predictive value was defined as the number of true-negative results as a fraction of the total number of true-negative and false-negative studies. The change in the benign biopsy rate with successive rounds of screening was tested for statistical significance using a χ2 test for trend. Because sensitivity and specificity vary with the chosen operating point (ie, the minimum BI-RADS score at which a report is considered to be positive), receiver operating characteristic (ROC) curves were plotted by using Microsoft Excel (Microsoft Corp, Redmond, Wash) and the corresponding areas under the ROC curve determined. The CBEs coded as suspicious for malignancy were recoded as BI-RADS 4 for the purpose of ROC curve construction.

RESULTS

The characteristics of the 236 study participants are listed in Table 1. The mean (range) age of participants at first screening was 46.6 years (26.4-64.8 years). A total of 205 women (87%) had a mammogram in the 15 months before starting the study. All women (100%) completed at least 1 round of screening, 136 (58%) completed at least 2 rounds, and 85 (36%) completed all 3 rounds. A total of 120 women are still undergoing annual screening. Thirty-one women left the study before completing all 3 rounds; 16 underwent bilateral mastectomy, 3 were too large to fit into the MRI machine, 3 stopped their participation due to pregnancy, 4 developed metastatic cancer, 4 were lost to follow-up, and 1 no longer wished to participate.

Breast Cancers

A total of 22 cancers (16 invasive and 6 ductal carcinoma in situ [DCIS]) were found in 21 women (1 woman had bilateral cancer). Multicentric cancer in 1 breast was defined as a single cancer. The characteristics of the patients with cancer, screening results, and tumor stage are listed in Table 2. The mean (range) age of the 21 women with cancer was 47.4 years (33.4-63.0 years). Seven women (33%) had previous breast cancer. Of the 22 cancers, 2 (9.1%) were detected by CBE, 8 (36%) by mammography, 7 (33%) of 21 by ultrasound, and 17 (77%) by MRI. Magnetic resonance imaging was significantly more sensitive than either mammography (P = .02) or ultrasound (P = .006).

All patients were followed up for a minimum of 1 year from the date of the last imaging examination. There was only 1 interval cancer, detected in a 40-year-old BRCA1 mutation carrier 7 months after her third screen (patient 59). At the time of her diagnosis, the tumor was visible with all 3 imaging modalities. In retrospect, it could be observed on previous screening MRI and mammogram. It is not possible to determine retrospectively if it was evident on ultrasound. Another woman (patient 323), who elected to have bi-
lateral mastectomy after her breast cancer was found, had a 2-mm focus of DCIS in the contralateral breast, which had not been detected 2 months earlier by any screening modality.

In combination, all 4 screening modalities had a sensitivity of 95% compared with 45% for mammography and CBE combined. By omitting ultrasound from the screening regimen, the overall sensitivity decreased from 95% to 86%. The sensitivity of all modalities other than MRI was 64%. The ROC curves for the entire BI-RADS range are shown in Figure 1. Seven cancers (32%) were detected by MRI but missed by all other modalities. Two cancers were detected by mammography alone (9.1%) and 2 detected by ultrasound alone (9.5%). Magnetic resonance imaging detected 9 (75%) of 12 cancers missed by conventional surveillance aging detected 9 (75%) of 12 cancers alone (9.5%).

Table 2. Characteristics of Patients With Cancer, Screening Results, and Tumor Stage

<table>
<thead>
<tr>
<th>Patient</th>
<th>Screen</th>
<th>Age, y</th>
<th>Mutation</th>
<th>Previous Breast Cancer</th>
<th>CBE</th>
<th>Mammography</th>
<th>Ultrasound</th>
<th>MRI</th>
<th>Histology</th>
<th>Size, cm</th>
<th>Nodal Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>5†</td>
<td>1</td>
<td>51</td>
<td>BRCA1</td>
<td>None</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>ID</td>
<td>0.5</td>
<td>NP</td>
</tr>
<tr>
<td>15†</td>
<td>1</td>
<td>51</td>
<td>BRCA2</td>
<td>Contralateral</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>DCIS†</td>
<td>0.5</td>
<td>NP</td>
</tr>
<tr>
<td>19†</td>
<td>1</td>
<td>46</td>
<td>BRCA1</td>
<td>None</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>ID</td>
<td>0.5</td>
<td>NP</td>
</tr>
<tr>
<td>23†</td>
<td>1</td>
<td>49</td>
<td>BRCA2</td>
<td>None</td>
<td>+</td>
<td>−</td>
<td>NP</td>
<td>+</td>
<td>ID</td>
<td>1.0</td>
<td>−</td>
</tr>
<tr>
<td>45†</td>
<td>2</td>
<td>47</td>
<td>BRCA2</td>
<td>None</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>ID</td>
<td>0.7</td>
<td>−</td>
</tr>
<tr>
<td>59†‡‡</td>
<td>3</td>
<td>40</td>
<td>BRCA1</td>
<td>None</td>
<td>NP§</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>ID</td>
<td>1.7</td>
<td>−</td>
</tr>
<tr>
<td>63‡</td>
<td>3</td>
<td>52</td>
<td>BRCA1</td>
<td>Contralateral</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ID</td>
<td>0.7</td>
<td>−</td>
</tr>
<tr>
<td>87‡</td>
<td>2</td>
<td>44</td>
<td>BRCA1</td>
<td>None</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ID</td>
<td>1.5</td>
<td>−</td>
</tr>
<tr>
<td>122‡‡</td>
<td>1</td>
<td>33</td>
<td>BRCA1</td>
<td>Contralateral</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ID</td>
<td>1.0</td>
<td>−</td>
</tr>
<tr>
<td>141</td>
<td>2</td>
<td>38</td>
<td>BRCA2</td>
<td>None</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>DCIS†</td>
<td>2.0</td>
<td>NP</td>
</tr>
<tr>
<td>210</td>
<td>2</td>
<td>54</td>
<td>BRCA1</td>
<td>None</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>ID</td>
<td>0.7</td>
<td>−</td>
</tr>
<tr>
<td>215</td>
<td>2</td>
<td>50</td>
<td>BRCA1</td>
<td>None</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>ID</td>
<td>0.6</td>
<td>−</td>
</tr>
<tr>
<td>225</td>
<td>2</td>
<td>39</td>
<td>BRCA2</td>
<td>None</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>ID</td>
<td>1.5</td>
<td>−</td>
</tr>
<tr>
<td>225</td>
<td>3</td>
<td>40</td>
<td>BRCA2</td>
<td>Contralateral</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>DCIS‡‡</td>
<td>6.0</td>
<td>NP</td>
</tr>
<tr>
<td>283</td>
<td>2</td>
<td>53</td>
<td>BRCA1</td>
<td>None</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>ID</td>
<td>1.0</td>
<td>−</td>
</tr>
<tr>
<td>323</td>
<td>4</td>
<td>48</td>
<td>BRCA1</td>
<td>Ipsilateral (different</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>ID</td>
<td>1.0</td>
<td>NP</td>
</tr>
<tr>
<td>346</td>
<td>1</td>
<td>46</td>
<td>BRCA2</td>
<td>None</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>DCIS†</td>
<td>1.5</td>
<td>NP</td>
</tr>
<tr>
<td>347</td>
<td>1</td>
<td>54</td>
<td>BRCA2</td>
<td>Ipsilateral (different</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>DCIS‡‡</td>
<td>3.0</td>
<td>NP</td>
</tr>
<tr>
<td>358</td>
<td>1</td>
<td>63</td>
<td>BRCA2</td>
<td>Contralateral</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>DCIS†</td>
<td>4.0</td>
<td>NP</td>
</tr>
<tr>
<td>384</td>
<td>1</td>
<td>35</td>
<td>BRCA2</td>
<td>None</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>ID</td>
<td>2.0</td>
<td>−</td>
</tr>
<tr>
<td>396</td>
<td>1</td>
<td>50</td>
<td>BRCA1</td>
<td>None</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>ID</td>
<td>1.5</td>
<td>5/11</td>
</tr>
<tr>
<td>412</td>
<td>1</td>
<td>60</td>
<td>BRCA2</td>
<td>None</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>IL</td>
<td>1.9</td>
<td>1/17</td>
</tr>
</tbody>
</table>

Abbreviations: CBE, clinical breast examination; DCIS, ductal carcinoma in situ; ID, infiltrating ductal; IL, invasive lobular; MRI, magnetic resonance imaging; NP, not performed.

‡Third annual CBE was performed at time of imaging but subsequent 6-month CBE was missed.

©2004 American Medical Association. All rights reserved.
tic MRI scan to clarify the status of an indeterminate or possibly suspicious lesion. This rate decreased at the second and third rounds of screening to 9.6% and 7.1%, respectively. For an additional 7.6% of the patients, a 6-month follow-up MRI was recommended for lesions that remained indeterminate. This rate decreased at the second and third screens to 2.9% and 2.4%, respectively. In the first round of screening, 5.1% of ultrasound examinations and 0.4% of mammograms resulted in the recommendation of a 6-month follow-up examination. A total of 2.1% of CBEs were also thought to be suspicious at the first round and CBE was repeated 3 months later. The corresponding rates for the second and third years combined were 3.2% for ultrasound, 0% for mammograms, and 0.4% for CBE.

A total of 34 (14%) of 236 women in the study have had a biopsy for what proved to be benign disease. Five women (2.1%) have had more than 1 biopsy. The benign biopsy rate was significantly higher at the first round of screening (26 [11%] of 236) than at the second (9 [6.6%] of 136) or third round (4 [4.7%] of 85; \( P = .05 \)). Only 5.1% of all benign biopsies were generated by a CBE.

Figure 1. Receiver Operating Characteristic Curves for Magnetic Resonance Imaging, Mammography, Ultrasound, and Clinical Breast Examination

Numbered data points indicate the sensitivity and specificity obtained if the minimum Breast Imaging Reporting and Data System (BI-RADS) grade for a positive point is varied from 1 to 5. For individual modalities, the areas under the receiver operating characteristic (ROC) curves are 0.89 for magnetic resonance imaging (MRI), 0.77 for mammography, 0.65 for ultrasound, and 0.48 for clinical breast examination (CBE). For combinations of modalities, the areas under the ROC curves are 0.93 for all 4 modalities, 0.94 for all excluding ultrasound, 0.91 for all excluding mammography, 0.81 for all excluding MRI, and 0.77 for mammography and CBE.

Figure 2. Mammography and Magnetic Resonance Imaging in BRCA2 Mutation Carrier With Less Than 25% Fibroglandular Density

False-negative mammograms in a 63-year-old BRCA2 mutation carrier demonstrating normal-appearing breasts that are composed of mostly fat (<25% fibroglandular density), classified as Breast Imaging Reporting and Data System (BI-RADS) 1. Sagittal, gadolinium-enhanced, fat-suppressed 3-dimensional spoiled gradient recalled magnetic resonance image of the right breast reveals clumped enhancement of more than 3.4 cm in a ductal distribution (arrowheads), classified as BI-RADS 4. Magnetic resonance imaging–guided wire localization and excisional biopsy revealed ductal carcinoma in situ.
or a mammogram finding; the rest were due to MRI or ultrasound. The PPV and specificity of MRI and ultrasound by year are given in Table 3. The PPV of MRI is consistently higher than that of ultrasound. The specificity of MRI is relatively low in the first year of screening compared with subsequent years. Of the 32 biopsies necessitated by findings with MRI alone, 22 (69%) could be performed under directed ultrasound guidance. The most common benign pathological findings were fibroadenoma (38%), fibrocystic changes (31%), and dense fibrosis (7.7%).

**COMMENT**

This study of 236 BRCA1 and BRCA2 mutation carriers demonstrates that the addition of annual MRI and ultrasound to mammography and CBE significantly improves the sensitivity of surveillance for detecting early breast cancers. The combination of MRI, ultrasound, and mammography had a sensitivity of 95% compared with 45% for mammography and CBE. Magnetic resonance imaging alone had a sensitivity of 77%. This study extends our study sample from our previous 96 to 236 BRCA carriers. Previously, we reported the results of the first screening examination only; however, now we report an average of 1.9 screening examinations per patient.

Only 36% of the breast cancers were detected by mammography. The sensitivity of mammography is inversely related to breast density and breast density is much higher, on average, in younger women than in older women. Furthermore, BRCA1-related cancers tend to be cellular with round pushing margins rather than scirrhouss with irregular infiltrating margins, resulting in a more benign mammographic appearance. BRCA1-associated tumors are also less likely to be associated with DCIS, which often develops microcalcifications that lead to detection by mammography, than are nonhereditary cancers or breast cancers in BRCA2 carriers.

The sensitivity of mammography in mutation carriers has been measured in several retrospective studies. In a small study of Asian patients with palpable breast cancers, only 4 (44%) of 9 tumors detected in BRCA1 mutation carriers could be observed on the preoperative mammogram (mean size, 4.1 cm) compared with 18 (95%) of 19 tumors in age-matched noncarriers (P = .03). Similarly, in a study of Ashkenazi Jewish women diagnosed with breast cancer younger than 50 years in Montreal, with breast cancers less than or equal to 2 cm in size, only 2 (25%) of 8 breast cancers could be observed on the preoperative mammogram of the mutation carriers compared with 27 (77%) of 35 in noncarriers (P = .009).

Prospective studies of cohorts undergoing mammographic surveillance have also been discouraging. In a series of 128 BRCA1 and BRCA2 mutation carriers reported by Brekelmans et al, 9 invasive breast cancers were detected after a median follow-up of 3 years. Five (56%) of the cancers were node-positive, 7 (78%) were more than 1 cm in size, and 4 (44%) appeared between rounds of screening mammography. Scheuer et al followed 164 mutation carriers for a mean of 2 years. Of the 10 cancers detected in women undergoing conventional surveillance only (mammography and breast self-examination), 2 (20%) were node-positive, 4 (40%) were more than 1 cm in size, and 5 (50%) were detected between screening mammograms. In contrast with these 2 studies, the proportion of interval cancers in our study was only 5%.

Although from a single center, our study is the largest study published to date of women with BRCA1 and BRCA2 mutations and the only one to include 4 screening modalities performed on the same day. Other preliminary reports of surveillance studies for high-risk women have also demonstrated better sensitivity of MRI compared with mammography. However, most previous studies included a relatively small number of patients with documented BRCA mutations and follow-up periods were short. In a large screening study of 196 high-risk women, Kuhl et al found 36 cancers. The sensitivity of MRI was 95% vs 34% for mammography and 42% for ultrasound. Morris et al screened 367 women at high risk for breast cancer using MRI. Biopsies were recommended for 64 women and 14 cancers were detected (8 DCIS and 6 invasive). These 2 single center studies were not restricted to BRCA mutation carriers. A total of 210 BRCA1 and BRCA2 mutations carriers have been included in a multicenter study from the Netherlands but only preliminary results have been published.

It is expected that cancers detected at the first round of screening (prevalent cancers) should be larger and more
likely to be lymph-node positive than cancers detected at subsequent screens (incident cancers). Three (23%) of 13 cancers detected at the first screen were more than 1 cm in size and 2 had axillary node involvement. Three (43%) of 7 cancers detected at the second screen were more than 1 cm in size but none were node-positive. The prevalence of cancer on the second screen (5.1%) was not appreciably lower than the proportion found to have cancer on the first screen (5.5%). There are 2 possible explanations for these unexpected findings. Subtle MRI changes on the first screen could have been missed, either because of relative lack of experience performing or reading MRI at the beginning of the study or because no previous MRI scan was available for comparison. Alternatively, the cancers could have grown so rapidly that, although undetectable at the first screen, within 1 year had grown beyond 1 cm. If rapid tumor growth is typical of BRCA-associated cancers, screening at 6-month intervals should be considered. Although the numbers are small, this is not supported by our year 3 results.

Ductal carcinoma in situ without invasion was only found in the BRCA2 mutation carriers. Other investigators have commented on the relative lack of DCIS in BRCA1 mutation carriers and suggest that among BRCA1 mutation carriers invasion occurs at an early stage of tumor development. Mammography appears to be a valuable adjunct to MRI for BRCA2 carriers because of the high incidence of DCIS in this subgroup. However, because of concerns about the potential carcinogenicity of ionizing radiation in younger women in general and BRCA1 mutation carriers in particular, some authors have suggested omitting mammography from the surveillance regimen for BRCA1 mutation carriers younger than 35 years.

To date, the reluctance to use breast MRI for surveillance of high-risk women outside the context of a clinical trial relates, to a large extent, to its high cost and relatively low specificity compared with mammography. It is encouraging that the MRI recall rates in our study decreased substantially from 26% on the first round of screening to 13% on the second round and 10% on the third round. Our overall specificity of 95% and PPV of 46% for MRI is comparable with the results of other investigators who have reported specificity rates ranging from 88% to 98% and PPVs ranging from 24% to 71%. Moreover, our results improved with successive rounds of screening. In all these studies, the definitions of specificity and PPV are based on biopsy rates rather than the number of screens requiring further workup. Two of the cancers in our study were detected by ultrasound alone. However, including ultrasound in the protocol resulted in more additional biopsies than MRI after the first year of screening. Whether the benefit of ultrasound is justified in light of the high false-positive rate remains to be observed. We did not observe any benefit from CBE over and above the combination of the 3 imaging modalities.

In conclusion, our results support the position that MRI-based screening is likely to become the cornerstone of breast cancer surveillance for BRCA1 and BRCA2 mutation carriers, but it is necessary to demonstrate that this surveillance tool lowers breast cancer mortality before it can be recommended for general use.

Author Contributions: Dr Warner had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Warner, Plewes, DeBoer, Yaffe, Narod.

Data acquired: Warner, Plewes, Hill, Causer, Zubovits, Jong, Cutrara, Messner, Meschinò, Piron, Narod.

Data analysis and interpretation of data: Warner, Hill, Causer, Jong, DeBoer, Yaffe, Narod.

Drafting of manuscript: Warner, Plewes, Narod.

Critical revision of the manuscript for important intellectual content: Hill, Causer, Zubovits, Jong, Cutrara, DeBoer, Yaffe, Messner, Meschinò, Piron.

Statistical analysis: DeBoer, Narod.

Obtained funding: Warner, Plewes.

Administrative, technical, or material support: Plewes, Hill, Causer, Jong, Cutrara, Yaffe, Piron, Narod.

Study supervision: Warner, Plewes.

Funding/Support: This work was supported by grants from the Canadian Breast Cancer Research Alliance, the Terry Fox Foundation, and funding from the International Breast MRI Consortium, the (Canadian) National Breast Cancer Fund, and the Papoff Family.

Role of the Sponsors: The Canadian Breast Cancer Research Alliance, the Terry Fox Foundation, the International Breast MRI Consortium, the National Breast Cancer Fund, and the Papoff Family did not participate in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.

Acknowledgment: We thank Glen Taylor, MD, Alice Chung, BC (MATS), Joan Glazier, MRT (RCB), Elizabeth Ramsay, PhD, Rhonda Walcarius, MRT(R), and Gina Markin, BSc, for their technical assistance; Belinda Curpen, MD, Taube Samuels, MD, Rene Shumak, MD, and Anne Marie Shorter, MD, for their interpretation of ultrasound results and mammograms; Michelle Kuzmich for helping prepare the manuscript; and the referring physicians. We are particularly grateful to the study participants.

REFERENCES


screening for breast cancer (MARIBS). J Exp Clin Canc-
17. Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast ultrasound and evalua-
18. Warner E, Plewes DB, Shumak RS, et al. Com-
parison of breast magnetic resonance imaging, mam-
mography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin On-
19. American College of Radiology (ACR) reporting system. In: Breast Imaging Reporting and Data Sys-
tem (BI-RADS). 2nd ed. Reston, Va: American Col-
lege of Radiology; 1993:15–18.
21. Greenman RL, Lenkinski RE, Schnall MD. Bilat-
eral imaging using separate interleaved 3D volumes and dynamically switched multiple receive coil ar-
23. Kuhl CK, Melcarek P, Klischik S, et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing le-
gnostic performance characteristics of architectural features revealed by high spatial-resolution MR im-
28. Mendelson EB, Berg WA, Merritt CR. Toward a stan-
dardized breast ultrasound lexicon, BI-RADS: ul-
29. Stavros AT, Thickman D, Rapp CL, et al. Solid breast nodules: use of sonography to distinguish be-
calization System: Proceedings of the Radiological So-
33. Kuhl CK, Morakabati N, Leutner CC, et al. MR imaging–guided large-core (14-gauge) needle bi-
34. Liberman L, Morris EA, Dershaw DD, et al. Fast MRI-guided vacuum-assisted breast biopsy: initial ex-
minimally invasive technique for diagnosis of enhanc-
36. Rosenberg RD, Hunt WC, Williamson MR, et al. Effects of age, breast density, ethnicity and estrogen replacement therapy on screening mammographic sen-
37. Lakhani SR, Jacquemier J, Sloane JP, et al. Mul-
tifactorial analysis of differences between sporadic breast cancers and breasts cancers involving BRCA1 and
40. Chang J, Yang WT, Choo HF. Mammography in
41. Goffin J, Chapuis PO, Wong N, Foulkes WD. Magnetic resonance imaging and mammography in
women with a hereditary risk of breast cancer. J Natl
42. Goss G, Sierra S. Current perspectives on radiation-
43. Chen JJ, Silver D, Cantor S, et al. BRCA1, BRCA2, and Rad 51 operate in a common DNA damage re-
44. Narod S, Lubinski J. Roles of radiation dose, che-
motherapy and hormonal factors in breast cancer fol-
45. Warren R. Screening women at high risk of breast